Perspective Therapeutics (CATX) Intangibles (2011 - 2026)
Perspective Therapeutics' (CATX) quarterly Intangibles came in at $40.0 million in Q2 2026, down 20.0% year-over-year from $50.0 million in Q2 2025, and little changed quarter-over-quarter from $40.0 million in Q1 2026.
Analysis
Perspective Therapeutics (CATX) Intangibles (2011 - 2026) Analysis & Trends
Perspective Therapeutics has disclosed Intangibles across 8 years of filings, most recently posting $40.0 million for Q2 2026.
- In Q2 2026, Intangibles fell 20.0% year-over-year to $40.0 million; the TTM figure through Jun 2026 stood at $40.0 million (down 20.0% YoY), while the FY2025 annual figure was $40.0 million, down 20.0% from the prior year.
- Intangibles came in at $40.0 million for Q2 2026 at Perspective Therapeutics, roughly flat from $40.0 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $50.0 million in Q1 2023 to a low of $40.0 million in Q4 2025.
- Average Intangibles over 4 years is $47.9 million, with a median of $50.0 million recorded in 2023.
- Year-over-year, Intangibles changed 0.0% in 2024 and slipped 20.0% in 2025.
- Over 4 years, Intangibles stood at $50.0 million in 2023, then changed by 0.0% to $50.0 million in 2024, then retreated by 20.0% to $40.0 million in 2025, then changed by 0.0% to $40.0 million in 2026.
- Per Business Quant data, the three most recent Intangibles figures were $40.0 million in Q2 2026, $40.0 million in Q1 2026, and $40.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 20.49 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 14.03 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 412.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.31 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 266.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 13.52 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | 40.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40.00 Mn |
| Mar 31, 2026 | 40.00 Mn |
| Dec 31, 2025 | 40.00 Mn |
| Sep 30, 2025 | 50.00 Mn |
| Jun 30, 2025 | 50.00 Mn |
| Mar 31, 2025 | 50.00 Mn |
| Dec 31, 2024 | 50.00 Mn |
| Sep 30, 2024 | 50.00 Mn |
| Jun 30, 2024 | 50.00 Mn |
| Mar 31, 2024 | 50.00 Mn |
| Dec 31, 2023 | 50.00 Mn |
| Sep 30, 2023 | 50.00 Mn |
| Jun 30, 2023 | 50.00 Mn |
| Mar 31, 2023 | 50.00 Mn |
| Jun 30, 2015 | 198,490.00 |
| Jun 30, 2014 | 223,756.00 |
| Jun 30, 2012 | 203,256.00 |
| Jun 30, 2011 | 203,194.00 |